#1 Clinical Trials Search in Europe

Linrodostat Mesilate

This article explores the use of Linrodostat Mesilate (BMS-986205), an IDO1 inhibitor, in clinical trials for advanced cancer treatment. The drug is being studied in combination with other immunotherapy agents to assess its safety, tolerability, and potential anti-tumor activity in patients with advanced malignant tumors. This innovative approach aims to provide new treatment options for individuals with difficult-to-treat cancers.

Table of Contents

What is LINRODOSTAT MESILATE?

LINRODOSTAT MESILATE, also known as BMS-986205, is an investigational drug being studied for the treatment of advanced cancers[1]. It is classified as an IDO1 inhibitor, which means it targets a specific enzyme in the body that plays a role in cancer growth[1]. This drug is currently being tested in clinical trials to determine its safety and effectiveness in treating various types of advanced malignant tumors.

How Does It Work?

LINRODOSTAT MESILATE works by inhibiting an enzyme called IDO1 (indoleamine 2,3-dioxygenase 1). This enzyme is often overactive in cancer cells and helps them evade the immune system. By blocking IDO1, LINRODOSTAT MESILATE may help the immune system recognize and attack cancer cells more effectively[1].

What Conditions Does It Treat?

The current clinical trial is focusing on patients with advanced malignant tumors. This term refers to cancers that are either:

  • Metastatic (spread to other parts of the body)
  • Unresectable (cannot be completely removed by surgery)
  • Incurable with standard treatments
The trial aims to test LINRODOSTAT MESILATE in various types of solid tumors that have reached an advanced stage[1].

Current Research

LINRODOSTAT MESILATE is being studied in a Phase 1/2 clinical trial. This trial is testing the drug in combination with other cancer immunotherapy drugs, including:

  • Nivolumab (an anti-PD-1 monoclonal antibody)
  • Relatlimab (an anti-LAG-3 monoclonal antibody)
  • Ipilimumab (an anti-CTLA-4 monoclonal antibody)
The main goals of this study are to:
  1. Determine the safety and tolerability of these drug combinations
  2. Find the best dose for treatment
  3. Investigate how effective these combinations are in treating advanced cancers[1]

How Is It Administered?

LINRODOSTAT MESILATE is given as a film-coated tablet that is taken by mouth (oral use)[1]. This form of administration is generally more convenient for patients compared to drugs that need to be given by injection or infusion.

Who Is Eligible for the Trial?

The trial has specific criteria for who can participate. Some key eligibility factors include:

  • Having a confirmed diagnosis of an advanced solid tumor that can be measured
  • Having tumor tissue available for biomarker analysis
  • Being in relatively good overall health (ECOG performance status of 0 or 1)[1]
Some factors that may exclude a person from participating include:
  • Having uncontrolled cancer that has spread to the brain
  • A history of lung disease called interstitial lung disease or pneumonitis
  • Having other active cancers that require treatment[1]

Safety and Effectiveness

As LINRODOSTAT MESILATE is still in the investigational stage, its full safety profile and effectiveness are not yet known. The current clinical trial is designed to gather this important information. Researchers will be closely monitoring:

  • Side effects and adverse events
  • How well the treatment works in shrinking tumors or stopping cancer growth
  • How long any positive effects last[1]
It’s important to note that as an experimental treatment, there may be unknown risks and benefits. Patients considering participating in this trial should discuss all potential risks and benefits with their healthcare provider.

Aspect Details
Drug Name Linrodostat Mesilate (BMS-986205)
Drug Class IDO1 inhibitor
Administration Oral, film-coated tablet
Trial Phase Phase 1/2
Target Condition Advanced Malignant Tumors
Combination Therapy With nivolumab and ipilimumab
Primary Objectives Safety, tolerability, DLTs, MTD, anti-tumor activity
Key Endpoints Adverse events, ORR, DCR, DOR, PFS
Eligibility Criteria Incurable solid malignancy, measurable disease, ECOG status 0-1

FAQ

  • What is Linrodostat Mesilate and how does it work? Linrodostat Mesilate, also known as BMS-986205, is an IDO1 inhibitor. It works by blocking an enzyme called IDO1, which can suppress the immune system's ability to fight cancer. By inhibiting this enzyme, Linrodostat Mesilate may help boost the immune system's response against cancer cells.
  • What type of cancer is being targeted in this clinical trial? This clinical trial is focusing on advanced malignant tumors, which are solid cancers that are either metastatic (spread to other parts of the body) or unresectable (cannot be completely removed by surgery).
  • How is Linrodostat Mesilate being administered in the trial? Linrodostat Mesilate is being administered as a film-coated tablet for oral use. It is being studied in combination with other immunotherapy drugs, such as nivolumab and ipilimumab.
  • What are the main objectives of this clinical trial? The main objectives are to determine the safety and tolerability of Linrodostat Mesilate when used in combination with other immunotherapy drugs, to identify the maximum tolerated dose, and to investigate its anti-tumor activity in patients with advanced malignant tumors.
  • Who is eligible to participate in this clinical trial? Eligible participants include those with histologically or cytologically confirmed incurable solid malignancies that are advanced (metastatic and/or unresectable), with measurable disease. They must have available tumor tissue for biomarker analysis and an ECOG performance status of 0 or 1.

Ongoing Clinical Trials on Linrodostat Mesilate

  • Study of Relatlimab, Nivolumab, and Drug Combination for Patients with Advanced Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    France Italy Spain

Glossary

  • IDO1 inhibitor: A type of drug that blocks the enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which can suppress the immune system's ability to fight cancer.
  • Advanced Malignant Tumors: Cancers that have spread beyond their original site or cannot be completely removed by surgery.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Unresectable: A tumor that cannot be completely removed by surgery due to its size, location, or spread.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or level of treatment.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease Control Rate (DCR): The percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response, and stable disease.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without the cancer growing or spreading.
  • Progression Free Survival (PFS): The length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.

References

  1. http://clinicaltrials.eu/trial/study-of-relatlimab-nivolumab-and-drug-combination-for-patients-with-advanced-cancer/